Hiraga Y, Abe M, Kikuchi K, Nakahashi M
Jpn J Antibiot. 1980 Oct;33(10):1111-24.
The therapeutic efficacy of cefoxitin (CFX) in chronic respiratory tract infection was evaluated in patients who poorly responded to other antibiotics. To 20 patients, CFX was administered 2 g b.i.d. intravenously by drip infusion. Clinical efficacy was judged based on the criteria by score. 1. Bacterial elimination rate with CFX was 73.7%. 2. A clinical cure rate was 80.0% was obtained by doctors in charge. 3. According to the score assessment, the overall clinical effectiveness rate was 60.0%, clinical symptom cure rate was 85.0% and improvement rate of X-ray findings was 55.0%. 4. Usefulness rate which was assessed by clinical effect and side effect was 70.0%. 5. No side effects and abnormal laboratory findings were observed in this study. We used the new antibiotic CFX in patients with chronic respiratory tract infections who responded poorly to other antibiotics and obtained satisfactory results. Especially CFX indicated more effective possibility in cases from whom Gram-negative bacilli was isolated.
对其他抗生素反应不佳的慢性呼吸道感染患者，评估了头孢西丁（CFX）的治疗效果。对20例患者，静脉滴注CFX，2g，每日两次。根据评分标准判断临床疗效。1. CFX的细菌清除率为73.7%。2. 主治医生得出临床治愈率为80.0%。3. 根据评分评估，总体临床有效率为60.0%，临床症状治愈率为85.0%，X线表现改善率为55.0%。4. 根据临床疗效和副作用评估的有效率为70.0%。5. 本研究中未观察到副作用和实验室检查异常。我们将新型抗生素CFX用于对其他抗生素反应不佳的慢性呼吸道感染患者，并取得了满意的结果。尤其是CFX对分离出革兰氏阴性杆菌的病例显示出更有效的可能性。
